Yi Ba

23PUBLICATIONS
28CO-AUTHORS
Molecular targetsApplied geophysicsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|May 11, 2026
The evolving global landscape of first-in-class oncology drug innovation.

|Sep 03, 2025
Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach.

Zhiying Gao, Laizhi Luo, Yueting Han

|Aug 17, 2025
Anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open-label, phase 1b clinical trial.

Ming Bai, Yao Lu, Lin Shen

|Feb 10, 2025
Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial.

Rui Liu, Zhi Ji, Xia Wang

|May 23, 2024
Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study.

Tao Ning, Danyang Li, Ting Deng

|Dec 26, 2023
Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer.

Ming Bai, Yao Lu, Chunmei Shi

Pageof 4

Frequent Collaborators

2 joint publications

Ting Deng

2 joint publications

Rui Liu

1 joint publications

Wu Sun

1 joint publications

Yi Wang